Phase II trial assessing the efficacy and tolerability of L 759274 in patients with generalised anxiety disorder.
Phase of Trial: Phase II
Latest Information Update: 28 May 2012
At a glance
- Drugs L 759274 (Primary)
- Indications Generalised anxiety disorder
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Merck & Co
- 28 May 2012 New trial record
- 20 Mar 2012 Results published in International Journal of Neuropsychopharmacology.